| January 16, 2014 | ISSUE NUMBER 334 VOL 1 |
Forecast
Top Line Thoughts on Trends That Will Shape the Industry in 2014
Two weeks in and the New Year already seems old. Yet members of Pharm Exec’s Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets — forward and backward — over the busy months ahead. Here, one of our external-facing experts, Les Funtleyder, weighs in ...Read more
Forecast
More Top Line Thoughts on 2014 Industry Trends
Pharm Exec EAB member Elys Roberts, President of Ipsos Healthcare North America, says industry’s all-important reputational scorecard is finally rebounding after years of declining confidence among a variety of stakeholders ...Read more
Capitalizing on Virtual Environments in a Rapidly Changing Pharmaceutical Marketplace
The Digital Pharma Revolution has not only arrived, it’s thriving! Today’s leading pharmacos are adopting virtual environments as part of their training and marketing strategies Virtual environments provide a rich, interactive online space conducive to learning, collaborating and networking. Discover how this powerful new channel has helped Pharma brand managers, trainers, physicians and KOLs alike. Download this whitepaper and sharpen your digital Pharma strategy for 2014!
Competition
The 7 Habits of Highly Effective Competitors
Biopharma’s best companies provide valuable lessons for preparing, planning, and playing to win. Stan Bernard outlines seven habits that make them highly effective ...Read more
Launch
Checking the Box on Early Commercialization
It may require true “out of the box” thinking, but failure to improve successful launch rates will doom your company to marginalization in the competitive fight for brand affinity — not to mention the prescriber loyalty that keeps medicines in play for the long haul, write Partha & Jayanthi Anbil ...Read more
|
|
|
|
 //Former President of Novartis Oncology Hervé Hoppenot was named President and Chief Executive Officer of Incyte Corporation (Wilmington, DE).//NovaBay Pharmaceuticals, Inc. (Emeryville, CA), appointed Mark M. Sieczkarek and Dr.Massimo Radaelli to its Board of Directors.//BioScrip, Inc. (Elmsford, NY) appointed Tricia Huong Thi Nguyen, M.D., to its Board of Directors.//Actavis plc (Dublin, Ireland) has restructured its U.S. Specialty Brands business into four units: Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations. Herm Cukier will lead Women's Healthcare; Charles Sabino, Jr., will lead Urology and GI; and Thomas Griffin, Jr., will lead Business Operations. The company has not yet finalized plans regarding leadership of the Dermatology and Established Brands business.// |
|
|
|
|
|
 |
|
|
|
| |
|
|
|
 |
|
 |
What in your opinion poses the biggest threat to the industry over the next five years?
|
|
|
|
